Fudan University Shanghai Cancer CenterShanghai, Shanghai
Disclosures:
2960 - Stereotactic Ablative Radiotherapy Combined with Fruquintinib and Tislelizumab in Metastatic Colorectal Cancer: Updated Findings from a Single-Arm, Prospective Phase II Trial (RIFLE)
Tuesday, October 1, 202412:45 PM – 2:00 PM ET
2961 - Short-Course Radiotherapy Combined with Chemotherapy and PD-1 Inhibitor in Proficient Mismatch Repair or Microsatellite Stable (pMMR/MSS) Low-Lying Early Rectal Cancer: Preliminary Findings from a Pro
.jpg "Yajie Chen, PhD photo")